Dilantin-125, Dilantin-30 Pediatric, Dilantin Infatab
PHENYTOIN SODIUM EXTENDED
PHENYTOIN SODIUM PROMPT
Classifications: central nervous system agent; anticonvulsant; hydantoin
Pregnancy Category: D
100 mg prompt release capsule; 30 mg, 100 mg sustained release capsule; 50 mg chewable tablet; 125 mg/5 mL suspension; 50 mg/mL injection
Hydantoin derivative chemically related to phenobarbital. Precise mechanism of anticonvulsant action is not known, but drug
use is accompanied by reduced voltage, frequency, and spread of electrical discharges within the motor cortex. Class IB antiarrhythmic
properties similar to those of lidocaine and tocainide (also class IB agents). Has class IB antiarrhythmic properties.
Inhibits seizure activity. In abnormal tissue causes slight increase in AV conduction velocity depressed by digitalis glycoside;
prolongs effective refractory period, suppresses ventricular pacemaker automaticity, and may slow conduction or cause complete
block in abnormal ventricular fibers.
To control tonic-clonic (grand mal) seizures, psychomotor and nonepileptic seizures (e.g., Reye's syndrome, after head trauma).
Also used to prevent or treat seizures occurring during or after neurosurgery. Is not effective for absence seizures.
Antiarrhythmic agent (phenytoin IV) especially in treatment of digitalis-induced arrhythmias; treatment of trigeminal neuralgia
Hypersensitivity to hydantoin products; rash; seizures due to hypoglycemia; sinus bradycardia, complete or incomplete heart
block; Adams-Stokes syndrome; pregnancy (category D), lactation.
Impaired liver or kidney function; alcoholism; blood dyscrasias; hypotension, heart block, bradycardia, severe myocardial
insufficiency, impending or frank heart failure; older adult, debilitated, gravely ill patients; pancreatic adenoma; diabetes
mellitus, hyperglycemia; respiratory depression; acute intermittent porphyria.
Adult: PO 1518 mg/kg or 1 g loading dose, then 300 mg/d in 13 divided doses, may be gradually increased by 100 mg/wk until
seizures are controlled IV 1518 mg/kg or 1 g loading dose, then 100 mg t.i.d.
Child: PO/IV 1520 mg/kg loading dose, then 5 mg/kg or 250 mg/m2 in 23 divided doses
- Ensure that sustained release form is not chewed or crushed. Must be swallowed whole.
- Do not give within 23 h of antacid ingestion.
- Shake suspension vigorously before pouring to ensure uniform distribution of drug.
- Note: Prompt release capsules and chewable tablets are not intended for once-a-day dosage since drug is too quickly bioavailable
and can therefore lead to toxic serum levels.
- Use sustained release capsules ONLY for once-a-day dosage regimens.
CNS: Usually dose-related: Nystagmus, drowsiness, ataxia, dizziness, mental confusion, tremors, insomnia, headache, seizures. CV: Bradycardia, hypotension, cardiovascular collapse, ventricular fibrillation, phlebitis. Special Senses: Photophobia, conjunctivitis, diplopia, blurred vision. GI: Gingival hyperplasia, nausea, vomiting, constipation, epigastric pain, dysphagia, loss of taste, weight loss, hepatitis, liver necrosis. Hematologic: Thrombocytopenia, leukopenia, leukocytosis, agranulocytosis, pancytopenia, eosinophilia; megaloblastic, hemolytic, or aplastic anemias. Metabolic: Fever, hyperglycemia, glycosuria, weight gain, edema, transient increase in serum thyrotropic (TSH) level, osteomalacia or
rickets associated with hypocalcemia and elevated alkaline phosphatase activity. Skin: Alopecia, hirsutism (especially in young female); rash: scarlatiniform, maculopapular, urticaria, morbilliform; bullous, exfoliative, or purpuric dermatitis; Stevens-Johnson syndrome, toxic epidermal necrolysis, keratosis, neonatal hemorrhage. Urogenital: Acute renal failure, Peyronie's disease. Respiratory: Acute pneumonitis, pulmonary fibrosis. Body as a Whole: Periarteritis nodosum, acute systemic lupus erythematosus, craniofacial abnormalities (with enlargement of lips); lymphadenopathy.
- Note: Verify correct rate of IV injection for administration to infants or children with physician.
- Inspect solution prior to use. May use a slightly yellowed injectable solution safely. Precipitation may be caused by refrigeration,
but slow warming to room temperature restores clarity.
PREPARE: Direct: Give undiluted. Use only when clear without precipitate.
ADMINISTER: Direct: Give 50 mg or fraction thereof over 1 min (25 mg/min in older adult or when used as antiarrhythmic). Follow with an injection
of sterile saline through the same in-place catheter or needle. Do not use solutions containing dextrose.
INCOMPATIBILITIES Solution/additive: 5% dextrose, amikacin, aminophylline, bretylium, cephapirin, codeine phosphate, dobutamine, hydromorphone, insulin, levorphanol, lidocaine, lincomycin, meperidine, metaraminol, methadone, morphine, nitroglycerin, norepinephrine, pentobarbital, procaine, secobarbital, streptomycin, sufentanil. Y-site: Amikacin, amphotericin B cholesteryl complex, bretylium, ciprofloxacin, clindamycin, diltiazem, dobutamine, enalaprilat, lidocaine, heparin, hydromorphone, potassium chloride, propofol, sufentanil, theophylline, TPN, vitamin B complex with C.
- Observe injection site frequently during administration to prevent infiltration. Local soft tissue irritation may be serious,
leading to erosion of tissues.
Phenytoin (hydantoins) may produce lower than normal values for dexamethasone or metyrapone tests; may increase serum levels of glucose, BSP, and alkaline phosphatase and may decrease PBI and urinary steroid levels.
Drug: Alcohol decreases phenytoin effects; other anticonvulsants may increase or decrease phenytoin levels; phenytoin may decrease absorption and increase metabolism of oral anticoagulants; phenytoin increases metabolism of corticosteroids, oral contraceptives, and nisoldipine, thus decreasing their effectiveness; amiodarone, chloramphenicol, omeprazole, and ticlopidine increase phenytoin levels; antituberculosis agents decrease phenytoin levels. Food: Folic acid, calcium, and vitamin D absorption may be decreased by phenytoin; phenytoin absorption may be decreased by enteral nutrition supplements. Herbal: Ginkgo may decrease anticonvulsant effectiveness.
Absorption: Completely absorbed from GI tract. Peak: 1.53 h prompt release; 412 h sustained release. Distribution: 95% protein bound; crosses placenta; small amount in breast milk. Metabolism: Oxidized in liver to inactive metabolites. Elimination: Metabolites excreted by kidneys. Half-Life: 22 h.
Assessment & Drug Effects
- Continuously monitor vital signs and symptoms during IV infusion and for an hour afterward. Watch for respiratory depression.
Constant observation and a cardiac monitor are necessary with older adults or patients with cardiac disease. Margin between
toxic and therapeutic IV doses is relatively small.
- Be aware of therapeutic serum concentration: 1020 mcg/mL; toxic level: 3050 mcg/mL; lethal level: 100 mcg/mL.
Steady-state therapeutic levels are not achieved for at least 710 d.
- Lab tests: Periodic serum phenytoin concentration; CBC with differential, platelet count, and Hct and Hgb; serum glucose,
serum calcium, and serum magnesium; and liver funtion tests.
- Observe patient closely for neurologic adverse effects following IV administration. Have on hand oxygen, atropine, vasopressor,
assisted ventilation, seizure precaution equipment (mouth gag, nonmetal airway, suction apparatus).
- Be aware that gingival hyperplasia appears most commonly in children and adolescents and never occurs in patients without
- Make sure patients on prolonged therapy have adequate intake of vitamin D-containing foods and sufficient exposure to sunlight.
- Monitor diabetics for loss of glycemic control.
- Check periodically for decrease in serum calcium levels. Particularly susceptible: patients receiving other anticonvulsants
concurrently, as well as those who are inactive, have limited exposure to sun, or whose dietary intake is inadequate.
- Observe for symptoms of folic acid deficiency: neuropathy, mental dysfunction.
- Be alert to symptoms of hypomagnesemia (see Appendix F); neuromuscular symptoms: tetany, positive Chvostek's and Trousseau's
signs, seizures, tremors, ataxia, vertigo, nystagmus, muscular fasciculations.
Patient & Family Education
- Be aware that drug may make urine pink or red to red-brown.
- Report symptoms of fatigue, dry skin, deepening voice when receiving long-term therapy because phenytoin can unmask a low
- Do not alter prescribed drug regimen. Stopping drug abruptly may precipitate seizures and status epilepticus.
- Do not to request/accept change in drug brand when refilling prescription without consulting physician.
- Understand the effects of alcohol: Alcohol intake may increase phenytoin serum levels, leading to phenytoin toxicity.
- Discontinue drug immediately if a measles-like skin rash or jaundice appears and notify physician.
- Be aware that influenza vaccine during phenytoin treatment may increase seizure activity. Understand that a change in dose
may be necessary.
- Do not breast feed while taking this drug.